Form D · Biotechnology
Checkmate Pharmaceuticals, Inc.
Cambridge, MA · CIK 0001651431
Offering snapshot reported Jun 18, 2020 · SEC filing
- Reported sold
- $85.1M Offering amount: $100M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 9, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 18, 2020 | Initial | $85,083,280 | No comparison | 17 | SEC filing |
| Apr 24, 2020 | Initial | $10,000,000 | No comparison | 4 | SEC filing |
| Jan 28, 2020 | Amendment | $15,999,999 | $8,000,003vs Aug 20, 2019 | 4 | SEC filing |
| Aug 20, 2019 | Initial | $7,999,996 | No comparison | 4 | SEC filing |
| Apr 1, 2019 | Amendment | $21,999,995 | $10,999,997vs Dec 12, 2018 | 4 | SEC filing |
| Dec 12, 2018 | Initial | $10,999,998 | No comparison | 4 | SEC filing |
| Jun 16, 2017 | Initial | $27,000,000 | No comparison | 3 | SEC filing |
| Feb 16, 2017 | Amendment | $25,000,000 | $14,970,000vs Aug 25, 2015 | 2 | SEC filing |
| Jun 30, 2016 | Amendment | $20,000,000 | $9,970,000vs Aug 25, 2015 | 2 | SEC filing |
| Aug 25, 2015 | Initial | $10,030,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-369265
$10,083,787 from conversion of promissory notes
Source: Form D, filed Jun 18, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles Abdalian | Executive |
| Chuck Abdalian | Executive |
| Ben Auspitz | Director |
| Karen Brennan | Executive |
| Kleem Chaudhary | Executive |
| Peter Colabuono | Director |
| Keith Flaherty | Director |
| Alan Fuhrman | Director |
| Corey Goodman | Director |
| Arthur Krieg | Director, Executive |
| Art Krieg | Director, Executive |
| Barry Labinger | Director, Executive |
| Jon Lieber | Executive |
| Jonathan Lieber | Executive |
| David Mauro | Executive |
| Michael Powell | Director |
| Ramani Varanasi | Executive |
| Robert Weisskoff | Director |
| James Wooldridge | Executive |
| Charles Yon | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
245 Main Street, 2 Nd Floor
Cambridge, MA, 02142
Cambridge, MA, 02142